Our portfolio

Biological drug development for novel biospecific drugs

Immunocore develops innovative biological therapeutics that use the power of the body’s own immune system to find and eradicate diseased cells. With the foundation’s support, the company is expanding its focus into infectious disease.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Series B
  • Partnered in
    2017
  • Investment lead
    David Rossow
  • Headquarters
    United Kingdom
  • Program strategy
    Discovery & Translational Sciences

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.